From: Prognostic and predictive biomarker developments in multiple myeloma
Identifier | Regimen | Subjects | Sensitivity/method | Status |
---|---|---|---|---|
NCT03948035 | Elo-KRd versus KRd prior to and after ASCT and maintenance with Elo-R versus R | 576 NDMM eligible for ASCT | NR/MFC | Recruiting |
NCT03652064 | Dara-VRd followed by Dara-Rd versus VRd followed by Rd | 395 NDMM patients for whom ASCT is not planned as initial therapy | 10–5/NGS | Active, not recruiting |
NCT03617731 | Isa-RVd versus RVd for induction, ASCT and Isa-R versus R for maintenance therapy | 662 NDMM eligible for ASCT | 10–5/NGF | Active, not recruiting |
NCT04751877 | Isa-RVd versus Isa-Rd | 270 NDMM non-eligible for ASCT | 10–5/NGS | Recruiting |